You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 8, August 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Topical Mupirocin Treatment of Impetigo Is Equal to Oral Erythromycin Therapy

Patricia M. Mertz; David A. Marshall; William H. Eaglstein, MD; Yvette Piovanetti, MD; Josephina Montalvo, MD

Arch Dermatol. 1989;125(8):1069-1073.


Abstract

• Topical antimicrobial therapy has not been effective in the past against cutaneous bacterial infections. In this study, a new topical antibiotic ointment, mupirocin, was compared with oral erythromycin ethylsuccinate in the treatment of impetigo. Seventy-five patients clinically diagnosed as having impetigo and with positive cultures of Staphylococcus aureus, Streptococcus pyogenes, or both were examined in an investigator-blinded study. Patients used topical mupirocin applied three times daily or the usual oral dose of erythromycin ethylsuccinate (30 to 50 mg/kg per day). Patients' lesions were examined clinically and cultured bacteriologically on days 0, 3, and 8, and 1 week after treatment. Susceptibility testing was performed on pathogens isolated to determine antibiotic resistance. Mupirocin treatment produced similar clinical results to oral erythromycin and was superior in the eradication of S aureus, including antibiotic-resistant S aureus. These results show topical mupirocin to be a safe and effective alternative to oral antibiotic therapy in the treatment of impetigo.

(Arch Dermatol. 1989;125:1069-1073)



Author Affiliations

From the Department of Dermatology and Cutaneous Surgery, University of Miami (Fla) School of Medicine (Ms Mertz, Mr Marshall, and Dr Eaglstein); and the Department of Public Health of the City of San Juan, Puerto Rico (Drs Piovanetti and Montalvo).


Footnotes

Accepted for publication March 15, 1989.

Reprint requests to Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, PO Box 016250 (R-250), Miami, FL 33101 (Dr Mertz).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Fusidic acid resistance in Staphylococcus aureus
Dobie and Gray
Arch. Dis. Child. 2004;89:74-77.
ABSTRACT | FULL TEXT  

Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial
Koning et al.
BMJ 2002;324:203-203.
ABSTRACT | FULL TEXT  

The Treatment of Staphyloccocus Aureus Infected Sore Nipples: A Randomized Comparative Study
Livingstone and Stringer
J Hum Lact 1999;15:241-246.
ABSTRACT  

Streptococcal Infections of Skin and Soft Tissues
Bisno and Stevens
NEJM 1996;334:240-246.
FULL TEXT  

Review of Mupirocin Ointment In the Treatment of Impetigo
Leyden
CLIN PEDIATR 1992;31:549-553.
 

Impetigo
ESTERLY et al.
Arch Pediatr Adolesc Med 1991;145:125-126.
ABSTRACT  

Dermatology
Dover and Arndt
JAMA 1990;263:2633-2635.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.